Evidence mapPaperPMID 39339653Full record

ArticleNutrients2024

Resistance Training and Nutritional Supplementation in Older Adults with Sarcopenia after Acute Disease: A Feasibility Study.

Delky Meza-Valderrama, Dolores Sánchez-Rodríguez, Yulibeth Curbelo Peña, Cindry Ramírez-Fuentes, Elena Muñoz-Redondo, Andrea Morgado-Pérez, Norma Ortíz-Agurto, Paola Finis-Gallardo, Ester Marco

Registry-linked trialAbstract read
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07345832 (The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07345832 narecruitingnot on this mapstarted 2026, after this paper: background citation

The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S): A Randomised Controlled Trial

TypeinterventionalSponsorThe University of Hong KongRan2026 to 2027Enrolled200ConditionsSarcopenia, Sarcopenia in Elderly, Fall Prevention in Healthy Aging, Frailty SyndromeArmsVolunteer-Engaged Lifestyle Optimisation via ICOPE for Sarcopenia program (VELO-S), Attention control
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Delky Meza-ValderramaRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08024 Barcelona, Catalonia, Spain.ORCID 0000-0001-9259-7745
Dolores Sánchez-RodríguezRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08024 Barcelona, Catalonia, Spain.ORCID 0000-0001-8662-5172
Yulibeth Curbelo PeñaRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08024 Barcelona, Catalonia, Spain.
Cindry Ramírez-FuentesRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08024 Barcelona, Catalonia, Spain.
Elena Muñoz-RedondoRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08024 Barcelona, Catalonia, Spain.ORCID 0000-0002-6288-0408
Andrea Morgado-PérezRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08024 Barcelona, Catalonia, Spain.
Norma Ortíz-AgurtoPhysical Medicine and Rehabilitation Department, National Institute of Physical Medicine and Rehabilitation, Panama City 0819, Panama.
Paola Finis-GallardoPhysical Medicine and Rehabilitation Department, National Institute of Physical Medicine and Rehabilitation, Panama City 0819, Panama.
Ester MarcoRehabilitation Research Group, Hospital del Mar Medical Research Institute, 08024 Barcelona, Catalonia, Spain.ORCID 0000-0002-3412-0356

Funding

Nutricia Research Foundation Project No. 2017-14
6 · The paper itself

Abstract

Resistance exercise and protein supplementation are recognized as effective treatment strategies for age-related sarcopenia; however, there are limited data on their feasibility, tolerability, and safety. The primary outcome of this study was feasibility, evaluated through the 15-item TELOS (Technological, Economics, Legal, Operational, and Scheduling) feasibility components and by recruitment, retention, and consent rates. Tolerability was measured by examining permanent treatment discontinuation, treatment interruption, exercise dose modification, early termination, rescheduling of missed sessions, losses to follow-up, attendance, and nutritional compliance. Safety was evaluated using the parameters provided by the European Medicines Agency, adapted for exercise interventions. Thirty-two subjects were recruited (average age 81.6 [SD 9.3] years). The TELOS components were assessed before the intervention; out of 15 questions relevant for successful implementation, 4 operational needs answers required specific actions to prevent potential barriers. The recruitment rate was 74%. Eleven patients (34.4%) had permanent treatment interruption (retention rate = 65.6%). Patients attended a mean of 23 (SD 12.0) exercise sessions, with a mean of 56 (SD 32.6) nutritional compliances. A total of 21 patients (65.6%) experienced adverse events unrelated to the intervention, while 7 patients (21.9%) presented adverse reactions to strength exercise. The main barriers to feasibility were operational components and recruitment challenges. Although the intervention was generally safe, the high rate of probable adverse effects, unrelated to the intervention but associated with the individual's baseline health condition, may affect adherence to treatment programs of this kind.

Indexed as

AftercareDietary SupplementsResistance TrainingSarcopeniaValeratesAgedAged, 80 and overCombined Modality TherapyFeasibility StudiesFemaleHumansMalePatient Acceptance of Health CareRandomized Controlled Trials as TopicTreatment Outcomebeta-hydroxyisovaleric acidValeratesfeasibilityhydroxy-methyl-butyrateprotein supplementationresistance exercisesarcopenia in older adults

Identifiers

PMID39339653
PMCPMC11434942

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.